Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2013 3
2014 2
2015 3
2016 4
2017 4
2018 10
2019 7
2020 5
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Results by year
Filters applied: . Clear all
Page 1
Calciphylaxis: risk factors, diagnosis, and treatment.
Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, Kamdar MM, Steele DJ, Thadhani RI. Nigwekar SU, et al. Am J Kidney Dis. 2015 Jul;66(1):133-46. doi: 10.1053/j.ajkd.2015.01.034. Epub 2015 May 7. Am J Kidney Dis. 2015. PMID: 25960299 Free PMC article. Review.
It is predominantly seen in patients with chronic kidney failure treated with dialysis (uremic calciphylaxis) but is also described in patients with earlier stages of chronic kidney disease and with normal kidney function. In this review, we discuss the available me …
It is predominantly seen in patients with chronic kidney failure treated with dialysis (uremic calciphylaxis) but is also desc …
Calciphylaxis.
Nigwekar SU, Thadhani R, Brandenburg VM. Nigwekar SU, et al. N Engl J Med. 2018 May 3;378(18):1704-1714. doi: 10.1056/NEJMra1505292. N Engl J Med. 2018. PMID: 29719190 Review. No abstract available.
Calciphylaxis.
Nigwekar SU. Nigwekar SU. Curr Opin Nephrol Hypertens. 2017 Jul;26(4):276-281. doi: 10.1097/MNH.0000000000000328. Curr Opin Nephrol Hypertens. 2017. PMID: 28375870 Free PMC article. Review.
PURPOSE OF REVIEW: Calciphylaxis remains a poorly understood vascular calcification disorder with predilection for patients with end-stage renal disease (ESRD). ...SUMMARY: The present review describes recent literature in the field of calciphylaxis. Calci
PURPOSE OF REVIEW: Calciphylaxis remains a poorly understood vascular calcification disorder with predilection for patients wi …
Sodium thiosulfate therapy for calcific uremic arteriolopathy.
Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr. Nigwekar SU, et al. Clin J Am Soc Nephrol. 2013 Jul;8(7):1162-70. doi: 10.2215/CJN.09880912. Epub 2013 Mar 21. Clin J Am Soc Nephrol. 2013. PMID: 23520041 Free PMC article.
BACKGROUND AND OBJECTIVE: Calcific uremic arteriolopathy (CUA) is an often fatal condition with no effective treatment. ...
BACKGROUND AND OBJECTIVE: Calcific uremic arteriolopathy (CUA) is an often fatal condition with no effective treatment. …
Statin use and calcific uremic arteriolopathy: a matched case-control study.
Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R. Nigwekar SU, et al. Am J Nephrol. 2013;37(4):325-32. doi: 10.1159/000348806. Epub 2013 Mar 21. Am J Nephrol. 2013. PMID: 23548843 Free PMC article.
BACKGROUND: Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is characterized by vascular calcification, thrombosis and intense inflammation. ...
BACKGROUND: Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is characterized by vascular c
Calciphylaxis from nonuremic causes: a systematic review.
Nigwekar SU, Wolf M, Sterns RH, Hix JK. Nigwekar SU, et al. Clin J Am Soc Nephrol. 2008 Jul;3(4):1139-43. doi: 10.2215/CJN.00530108. Epub 2008 Apr 16. Clin J Am Soc Nephrol. 2008. PMID: 18417747 Free PMC article. Review.
BACKGROUND AND OBJECTIVES: Calciphylaxis, or calcific uremic arteriolopathy, is a well-described entity in end-stage kidney disease and renal transplant patients; however, little systematic information is available on calciphylaxis from nonuremi …
BACKGROUND AND OBJECTIVES: Calciphylaxis, or calcific uremic arteriolopathy, is a well-described entity in end-s …
Multidisciplinary approach to calcific uremic arteriolopathy.
Nigwekar SU. Nigwekar SU. Curr Opin Nephrol Hypertens. 2015 Nov;24(6):531-7. doi: 10.1097/MNH.0000000000000175. Curr Opin Nephrol Hypertens. 2015. PMID: 26371529 Review.
PURPOSE OF REVIEW: Calcific uremic arteriolopathy (CUA), as known as calciphylaxis, is a rare and poorly understood disease seen predominantly in end stage renal disease patients. ...
PURPOSE OF REVIEW: Calcific uremic arteriolopathy (CUA), as known as calciphylaxis, is a rare and poorly underst …
Revisiting therapeutic options for calciphylaxis.
Seethapathy H, Nigwekar SU. Seethapathy H, et al. Curr Opin Nephrol Hypertens. 2019 Sep;28(5):448-454. doi: 10.1097/MNH.0000000000000520. Curr Opin Nephrol Hypertens. 2019. PMID: 31169527 Review.
PURPOSE OF REVIEW: Calciphylaxis is a disorder of cutaneous microvascular calcification and thrombosis leading to chronic, excruciatingly painful, progressive wounds with a high risk of sepsis and death. The diagnosis and treatment of calciphylaxis presents s …
PURPOSE OF REVIEW: Calciphylaxis is a disorder of cutaneous microvascular calcification and thrombosis leading to chronic, exc …
Calciphylaxis.
Nigwekar SU, Thadhani R, Brandenburg VM. Nigwekar SU, et al. N Engl J Med. 2018 Jul 26;379(4):399-400. doi: 10.1056/NEJMc1807324. N Engl J Med. 2018. PMID: 30044942 No abstract available.
Assessment of outcomes of calciphylaxis.
Gabel CK, Nguyen ED, Chakrala T, Blum AE, François J, Chand S, Rrapi R, Baker O, Dobry AS, Garza-Mayers AC, Ko LN, Shah R, St John J, Nigwekar SU, Kroshinsky D. Gabel CK, et al. J Am Acad Dermatol. 2021 Oct;85(4):1057-1064. doi: 10.1016/j.jaad.2020.10.067. Epub 2020 Oct 29. J Am Acad Dermatol. 2021. PMID: 33130181
BACKGROUND: Calciphylaxis is a rare thrombotic vasculopathy characterized by high morbidity and mortality. ...RESULTS: Six-month mortality was 37.2%, and 1-year mortality was 44.1%. Patients with nephrogenic calciphylaxis had worse survival than those with nonnephro …
BACKGROUND: Calciphylaxis is a rare thrombotic vasculopathy characterized by high morbidity and mortality. ...RESULTS: Six-month mort …
39 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page